RxDoctor Payments DataLook up a doctor →

Mohammad Raja, MD

Interventional Cardiology · El Paso, TXNPI 1548250244

Payments from drug & device makers

$318,855in general payments, 2019–2025

Across 1,200 payments — averaging $265.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$112K
  • M.a. Med Alliance S.A.$49K
  • Terumo Medical Corporation$34K
  • Cardiovascular Systems Inc.$28K
  • Philips North America LLC$26K
  • Shockwave Medical, Inc$25K
  • plus $45K from 54 others
$10,900in research payments, 2019–2025

Across 5 payments — averaging $2180.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$8K
  • Medtronic$3K

What the payments were for

  • Consulting fees$69,91326%
  • Speaking & faculty fees$139,80752%
  • Travel & lodging$15,5696%
  • Food & beverage$43,14616%
  • Education$1040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)305$111,842
M.a. Med Alliance S.A.22$48,592
Terumo Medical Corporation69$34,231
Cardiovascular Systems Inc.75$28,310
Philips North America LLC68$25,745
Shockwave Medical, Inc32$25,069
Janssen Scientific Affairs, LLC9$5,344
Endologix LLC7$4,214
Otsuka Pharmaceutical Development & Commercialization, Inc.1$3,675
Inari Medical, Inc.47$3,139
Asahi Intecc USA, Inc.15$3,073
Johnson & Johnson87$2,907
Penumbra, Inc.8$2,472
Stryker19$2,274
Bard Peripheral Vascular, Inc.28$2,253
Abbott33$1,979
Angiodynamics, Inc.12$1,875
Cordis US CORP.7$1,474
Intact Vascular, Inc.12$1,142
Novartis63$969
Boston Scientific31$853
W. L. Gore & Associates, Inc.18$823
Reflow Medical Inc6$722
E.r. Squibb & Sons, L.L.C.56$648
Pfizer41$628
Amgen28$489
Surmodics, Inc.6$454
Biotronik Inc.6$441
Boehringer Ingelheim17$350
Limflow Inc.1$317
Integra Lifesciences Corporation2$254
Asahi Intecc CO., LTD.2$221
Cagent Vascular Inc1$200
Merck8$199
Osiris Therapeutics Inc.2$191
EKOS Corporation2$183
Abiomed1$147
Astellas Pharma US Inc4$128
Sanofi-aventis U.S. LLC7$112
Tactile Systems Technology Inc7$107
Misonix Inc3$93
Smith+Nephew1$90
Novo Nordisk4$86
Veryan Medical Incorporated1$80
Amarin Pharma, Inc.4$79
AstraZeneca4$58
Terumo BCT, Inc.1$47
Chiesi USA, Inc.3$40
Reapplix Inc.1$36
Lexicon Pharmaceuticals, Inc.2$31
Impulse Dynamics (USA) Inc.1$24
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.2$23
Scpharmaceuticals Inc.1$21
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$21
Kiniksa Pharmaceuticals International, PLC1$21
Insmed, Inc.1$19
Z-medica, LLC1$18
Lantheus Medical Imaging, Inc.1$17
Vantis Vascular, Inc.1$0
Cardio Flow, Inc.1$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$318,855 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$810,207
Medicare patients
504
Services billed
6,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$381,171
XareltoRivaroxaban226$274,856
EntrestoSacubitril/Valsartan58$79,172
BrilintaTicagrelor11$11,194
Ranolazine ErRanolazine65$9,017
ClopidogrelClopidogrel Bisulfate513$5,710
Metoprolol Succinate166$2,087
Atorvastatin Calcium191$1,774
Cilostazol54$1,606
Amiodarone Hcl44$1,192
Prasugrel Hcl13$1,087
Carvedilol134$1,016
Losartan Potassium83$968
Metoprolol Tartrate136$952
Hydralazine Hcl34$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$628$381,171291 claims
Johnson & JohnsonXarelto$2,907$274,856226 claims
NovartisEntresto$969$79,17258 claims
AstraZenecaBrilinta$58$11,19411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →